Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

835.80INR
18 Apr 2019
Change (% chg)

Rs2.85 (+0.34%)
Prev Close
Rs832.95
Open
Rs833.00
Day's High
Rs837.60
Day's Low
Rs820.95
Volume
1,120,493
Avg. Vol
1,900,500
52-wk High
Rs986.10
52-wk Low
Rs719.80

Latest Key Developments (Source: Significant Developments)

India's Lupin Gets FDA Approval For Testosterone Gel
Thursday, 11 Apr 2019 

April 11 (Reuters) - Lupin Ltd ::GETS FDA APPROVAL FOR TESTOSTERONE GEL.  Full Article

Lupin Launches Fluocinonide Ointment USP 0.05 Pct
Thursday, 28 Mar 2019 

March 28 (Reuters) - Lupin Ltd ::LUPIN LAUNCHES FLUOCINONIDE OINTMENT USP 0.05%.  Full Article

Lupin Gets USFDA Approval For Tadalafil Tablets Usp
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Lupin Ltd ::GETS US FDA APPROVAL FOR TADALAFIL TABLETS USP.  Full Article

Lupin's Mammalian Facility Gets European Good Manufacturing Practice Certificate
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Lupin Ltd ::GETS EUROPEAN GOOD MANUFACTURING PRACTICE CERTIFICATE FOR ITS MAMMALIAN FACILITY IN PUNE.ETANERCEPT BIOSIMILAR IS INTENDED TO BE MANUFACTURED IN MAMMALIAN FACILITY IN PUNE.  Full Article

Lupin Says YL Biologics Gets Approval To Manufacture And Sell Biosimilar Etanercept In Japan
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Lupin Ltd ::SAYS YL BIOLOGICS LIMITED RECEIVES APPROVAL TO MANUFACTURE AND SELL BIOSIMILAR ETANERCEPT IN JAPAN.  Full Article

Lupin Launches Generic Levothyroxine Sodium Tablets
Friday, 22 Mar 2019 

March 22 (Reuters) - Lupin Ltd ::LAUNCHES GENERIC LEVOTHYROXINE SODIUM TABLETS.  Full Article

Lupin Says USFDA Classified Inspection Of Co's Mandideep Facility As OAI
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Lupin Ltd ::U.S. FDA CLASSIFIES THE INSPECTION OF COMPANY'S MANDIDEEP (UNIT 1) FACILITY AS OAI (OFFICIAL ACTION INDICATED).USFDA STATED THAT FACILITY MAY BE SUBJECT TO REGULATORY/ ADMINISTRATIVE ACTION.NO NEW DMF AND ANDA APPLICATIONS PENDING REVIEW OR APPROVAL FROM THE MANDIDEEP (UNIT 1) FACILITY.USFDA STATED IT MAY WITHHOLD APPROVAL OF ANY PENDING APPLICATIONS OR SUPPLEMENTS IN WHICH THIS FACILITY IS LISTED.DOES NOT BELIEVE THAT CLASSIFICATION WILL IMPACT OR DISRUPT SUPPLIES OR EXISTING REVENUES FROM OPERATIONS OF THIS FACILITY.LUPIN SAYS IN PROCESS OF SENDING FURTHER UPDATES OF ITS CORRECTIVE ACTIONS TO THE U.S. FDA AND REMAINS HOPEFUL OF A POSITIVE OUTCOME.  Full Article

India's Lupin Seeks Shareholders' Nod For Continuation Of Directorship Of Manju D. Gupta, Chairman, Non-Executive Director
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Lupin Ltd ::SEEKS SHAREHOLDERS' NOD FOR CONTINUATION OF DIRECTORSHIP OF MANJU D. GUPTA, CHAIRMAN, NON-EXECUTIVE DIRECTOR.  Full Article

Lupin Launches Tadalafil Tablets USP
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Lupin Ltd ::SAYS CO LAUNCHES TADALAFIL TABLETS USP.  Full Article

India's Lupin Gets FDA Approval For Levothyroxine Sodium Tablets
Monday, 21 Jan 2019 

Jan 21 (Reuters) - Lupin Ltd ::GETS FDA APPROVAL FOR LEVOTHYROXINE SODIUM TABLETS USP.  Full Article

RPT-ICRA ratings for Indian debt instruments-Feb 26

(Repeating to add more ratings.) Feb 26 Below are the ratings awarded by Investment Information Credit Rating Agency Ltd. (ICRA) for local debt instruments as of February 25, 2019. COMPANY INSTRUMENT RATING AMOUNT MOVEMENT (RS.MLN) ------ ---------- ------ ----- --------- SHORT TERM RATINGS: -------------